Progenics and Curium Announced European Collaboration for Prostate Cancer Imaging Agent PyL

Publisher: The Insight Partners

Curium and Progenics entered into a collaboration to develop and commercialize PyL in Europe.  The European radiopharmaceuticals market is expected to witness significant growth during the forecast period, due to factors such as, rising prevalence of neurologic disorders such as, Alzheimer’s and others along with the developments made by the players operating in the region.

Curium is a pharmaceutical company which is engaged in developing, manufacturing and supplying world-class radiopharmaceutical products to customers across the globe. With the industry’s most extensive vertically-integrated manufacturing network, the company is majorly focusing on nuclear medicine business. The company offers regional based radiopharmaceutical products across the globe.

Curium headquartered in Paris, France and serves their customers in more than 60 countries across the globe. The company is a trusted partner to public and private hospitals, radiopharmacies and imaging centres worldwide. The company has a direct presence in China, India, Turkey, Mexico and a distributor network panning Middle East, Africa, Australia, Latam and Asia Pacific. Curium has been collectively formed by the IBA Molecular and Mallinckrodt Nuclear Medicine, in April 2017.